Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 7/20 | 0.35 |
| ▸ | CA2 | P00918 | 7/20 | 0.35 |
| ▸ | CA4 | P22748 | 7/20 | 0.35 |
| ▸ | CA7 | P43166 | 7/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2796421 | 0.85 | MAOA (0.43) | MAOACA1CA2CA4CA7 | |
| SCHEMBL2800260 | 0.83 | MAOA (0.41) | MAOACA1CA2CA4CA7 | |
| SCHEMBL2796446 | 0.83 | TOP2A (0.48) | MAOACA1CA2CA4CA7 | |
| SCHEMBL2798646 | 0.83 | F10 (0.53) | F10 | |
| SCHEMBL2796451 | 0.82 | MAOA (0.42) | MAOACA1CA2CA4CA7 | |
| SCHEMBL2800498 | 0.81 | MAOA (0.41) | MAOACA1CA2CA4CA7 | |
| SCHEMBL13232193 | 0.74 | F10 (0.66) | F10 | |
| SCHEMBL2798082 | 0.73 | F10 (0.43) | MAOAF10 | |
| SCHEMBL2800382 | 0.71 | F10 (0.45) | MAOAF10 | |
| SCHEMBL3038229 | 0.70 | MAOA (0.53) | MAOAF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288423-B2 | FXa inhibitors with cyclic amidines as P4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof | LEGOCHEM BIOSCIENCE LTD. (KR) | 2012-10-16 | — | — | US | disclosed |
| US-20100184781-A1 | FXA INHIBITORS WITH CYCLIC AMIDINES AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF | LEGOCHEM BIOSCIENCE LTD. (KR) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184781-A1 | FXA INHIBITORS WITH CYCLIC AMIDINES AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF | F12, F2, TFPI | MAOA 1142/4885CA1 1198/4885CA2 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.